Thyroid nodules are common, usually asymptomatic, and often pose minimal risk to the
affected patient. However, 10–15% prove malignant and serve as the rationale for …

Background Molecular tests are being used increasingly as an auxiliary diagnostic tool so
as to avoid a diagnostic surgery approach for cytologically indeterminate thyroid nodules …

Thyroid cancer is the most common endocrine malignancy with an estimated 43,800 new
cases to be diagnosed in 2022 and representing the 7th most common cancer in women …

Abstract Context The Afirma® GSC aids in risk stratifying indeterminate thyroid nodule
cytology (ITN). The 2018 GSC validation study (VS) reported a sensitivity (SN) of 91 …

Over the past 3 decades, advances in the molecular genetics of thyroid cancer (TC) have
been translated into diagnostic tests, prognostic markers, and therapeutic agents. The main …

Thyroid nodules, with a prevalence of almost 25% in the general population, are a common
occurrence. Their prevalence varies considerably depending on demographics such as age …

Background: Thyroid nodules with indeterminate cytology are increasingly subjected to
molecular testing. We evaluated the diagnostic performances of Afirma Genomic …

Objective The objective of this systematic review and meta-analysis was to evaluate the
diagnostic performance of the second-generation molecular tests in the diagnosis of thyroid …

Thyroid cancer is the most common endocrine malignancy, with increasing incidence over
the past few decades. Fine needle aspiration (FNA) biopsy is the gold standard for …

Background: Molecular testing (MT) refines risk stratification for thyroid nodules that are
indeterminate for cancer by fine needle aspiration (FNA) cytology. Criteria for selecting …